Comparative Effectiveness Rational vs Rationing

Private Payer and Physician Perspectives on How CE Will Change US Healthcare

Xcenda’s recent payer market research shows that 77% of payers indicated they will use comparative effectiveness data to evaluate coverage.  The insights uncovered in this report will guide manufacturers as they consider how comparative effectiveness studies can be utilized to demonstrate a product’s value and provide stakeholders with the evidence required to maximize patient access. The report also includes strategic analysis of the implications that new comparative effectiveness data may have on private payer coverage and reimbursement.  Access nearly 200 pages with specific data including:

• Current perspectives and future predictions on CE from managed care stakeholders
  
• The impact of comparative effectiveness on oncology
  
• A look into the future of comparative effectiveness across stakeholders
  
• Current issues shaping the development of CE research
  
• Support and opposition for “comparative cost-effectiveness”
  
• The United States’ unique global position on CE
  
• CE vs evidence-based medicine
  
• A detailed look at historic and future legislative directives related to CE
  
• The FDA’s role in CE research
  
• Implications for manufacturers

Turn to Xcenda for immediate access to market data that can improve your product’s success.